Yangfan Cheng

Yangfan Cheng

Auto-generated profile, based on publicly available information

Yangfan Cheng

Department of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatric, West China Hospital of Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Journal of Translational Internal Medicine
Verified
Journal Article
Open access
PDF file
YCYangfan Cheng
Yangfan Cheng
SZSirui Zhang
Sirui Zhang
HSHuifang Shang
Huifang Shang
Huntington’s disease (HD) is a devastating, autosomal-dominant inherited, neurodegenerative disorder characterized by progressive motor deficits, cognitive impairments, and neuropsychiatric symptoms. It is caused by excessive cytosine-adenine-guanine (CAG) trinucleotide repeats within the huntingtin gene (HTT). Presently, therapeutic interventions capable of altering the trajectory of HD are lacking, while medications for abnormal movement and psychiatric symptoms are limited. Numerous pre-clinical and clinical studies have been conducted and are currently underway to test the efficacy of therapeutic approaches targeting some of these mechanisms with varying degrees of success. In this review, we update the latest advances on new promising molecular-based therapeutic strategies for this disorder, including DNA-targeting techniques such as zinc-finger proteins, transcription activator-like effector nucleases, and CRISPR/Cas9; post-transcriptional huntingtin-lowering approaches such as RNAi, antisense oligonucleotides, and small-molecule splicing modulators; and novel methods to clear the mHTT protein, such as proteolysis-targeting chimeras. We mainly focus on the ongoing clinical trials and the latest pre-clinical studies to explore the progress of emerging potential HD therapeutics.

28 March 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
YWYanyun Wu
Yanyun Wu
YCYangfan Cheng
Yangfan Cheng
YXYi Xiao
Yi Xiao
HSHuifang Shang
Huifang Shang
RORuwei Ou
Ruwei Ou
Background: Parkinson disease (PD) is a common neurodegenerative disease characterized by both motor and nonmotor symptoms. Cognitive impairment often occurs early in the disease and can persist throughout its progression, severely impacting patients’ quality of life. The utilization of machine learning (ML) has recently shown promise in identifying cognitive impairment in patients with PD. Objective: This study aims to summarize different ML models applied to cognitive impairment in patients with PD and to identify determinants for improving diagnosis and predictive power for early detection of cognitive impairment. Methods: PubMed, Cochrane, Embase, and Web of Science were searched for relevant articles on March 2, 2024. The risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Bivariate meta-analysis was used to estimate pooled sensitivity and specificity results, presented as odds ratio (OR) and 95% CI. A summary receiver operator characteristic (SROC) curve was used. Results: A total of 38 articles met the criteria, involving 8564 patients with PD and 1134 healthy controls. Overall, 120 models reported sensitivity and specificity, with mean values of 71.07% (SD 13.72%) and 77.01% (SD 14.31%), respectively. Predictors commonly used in ML models included clinical features, neuroimaging features, and other variables. No significant heterogeneity was observed in the bivariate meta-analysis, which included 12 studies. Using sensitivity as the metric, the combined sensitivity and specificity were 0.76 (95% CI 0.67-0.83) and 0.83 (95% CI 0.76-0.88), respectively. When specificity was used, the combined values were 0.77 (95% CI 0.65-0.86) and 0.76 (95% CI 0.63-0.85), respectively. The area under the curves of the SROC were 0.87 (95% CI 0.83-0.89) and 0.83 (95% CI 0.80-0.86) respectively. Conclusions: Our findings provide a comprehensive summary of various ML models and demonstrate the effectiveness of ML as a tool for diagnosing and predicting cognitive impairment in patients with PD. Trial Registration: PROSPERO CRD42023480196; https://www.crd.york.ac.uk/PROSPERO/view/CRD42023480196

17 December 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YZYang Zhang
Yang Zhang
CCChaoyue Chen
Chaoyue Chen
YCYangfan Cheng
Yangfan Cheng
YTYuen Teng
Yuen Teng
WGWen Guo
Wen Guo
JXJianguo Xu
Jianguo Xu
Objectives: To investigate the ability of radiomics features from MRI in differentiating anaplastic oligodendroglioma (AO) from atypical low-grade oligodendroglioma using machine-learning algorithms. Methods: A total number of 101 qualified patients (50 participants with AO and 51 with atypical low-grade oligodendroglioma) were enrolled in this retrospective, single-center study. Forty radiomics features of tumor images derived from six matrices were extracted from contrast-enhanced T1-weighted (T1C) images and fluid-attenuation inversion recovery (FLAIR) images. Three selection methods were performed to select the optimal features for classifiers, including distance correlation, least absolute shrinkage and selection operator (LASSO), and gradient boosting decision tree (GBDT). Then three machine-learning classifiers were adopted to generate discriminative models, including linear discriminant analysis, support vector machine, and random forest (RF). Receiver operating characteristic analysis was conducted to evaluate the discriminative performance of each model. Results: Nine predictive models were established based on radiomics features from T1C images and FLAIR images. All of the classifiers represented feasible ability in differentiation, with AUC more than 0.840 when combined with suitable selection method. For models based on T1C images, the combination of LASSO and RF classifier represented the highest AUC of 0.904 in the validation group. For models based on FLAIR images, the combination of GBDT and RF classifier showed the highest AUC of 0.861 in the validation group. Conclusion: Radiomics-based machine-learning approach could potentially serve as a feasible method in distinguishing AO from atypical low-grade oligodendroglioma.

12 March 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RLRuwen Liu
Ruwen Liu
SZSirui Zhang
Sirui Zhang
YXYi Xiao
Yi Xiao
YCYangfan Cheng
Yangfan Cheng
HSHuifang Shang
Huifang Shang
Background: Parkinson disease (PD) is a progressive neurodegenerative disorder with increasing global prevalence, necessitating innovative management. Digital health interventions (DHIs) offer potential advantages for PD care; yet, a comprehensive systematic review and synthesis across all DHI types and core outcomes is still lacking. Objective: This review aimed to assess the effectiveness of DHIs for improving motor symptoms, nonmotor symptoms, and quality of life in patients with PD and to summarize the reach, uptake, and feasibility. Methods: We searched PubMed, Ovid Embase, Web of Science, CINAHL, Cochrane Central Register of Controlled Trials, and APA PsycINFO up to November 2025. Pooled standardized mean differences (SMDs) were calculated using random-effects models. We calculated 95% prediction intervals (PIs) to estimate the true effects. The revised Cochrane Risk of Bias 2 tool was used to assess risk of bias. Heterogeneity was assessed using I2, τ2, and 95% PI. Subgroup analyses, meta-regression, and sensitivity analyses were conducted to address heterogeneity and potential bias. The quality of evidence was assessed using GRADE (Grading of Recommendations Assessment, Development, and Evaluation). Results: The review included 112 randomized controlled trials involving 5594 participants. Significant postintervention improvements were identified in motor symptoms (SMD=–0.39, 95% CI –0.60 to –0.18, 95% PI –1.75 to 0.99; I2=80.3%) and overall nonmotor symptoms (SMD=–0.26, 95% CI –0.49 to –0.03, 95% PI –0.56 to 0.03; I2=13.8%), including cognitive function (SMD=0.47, 95% CI 0.22 to 0.72, 95% PI –0.41 to 1.35; I2=63.5%) and psychiatric symptoms (SMD=–0.42, 95% CI –0.74 to –0.09, 95% PI –1.82 to –0.99; I2=85.4%); however, there was no significant enhancement in quality of life (SMD=–0.19, 95% CI –0.47 to 0.09, 95% PI –1.50 to 1.12; I2=81.2%). The certainty of evidence was very low for quality of life, motor, and psychiatric symptoms and low for cognitive function and overall nonmotor symptoms. Improvements in motor symptoms and cognitive function remained stable at follow-up. Meta-regression analysis indicated that age, percentage of female participants, and supervision mode were possible sources of heterogeneity. Overall, 94 studies reported reach (median 37.5%), 38 reported fidelity (95.7%), and 105 reported dropout rates (9.1%). Conclusions: In contrast to previous reviews focused on single technologies or outcomes, this review provided the first comprehensive synthesis across all DHI types on multiple outcomes and indicated their potential as nonpharmacological interventions for PD management. However, current evidence is of low to very low certainty, and wide 95% PIs, together with high risk of bias and substantial heterogeneity, indicate considerable uncertainty regarding the true effect in future implementations. Therefore, findings should be interpreted with caution. These findings provide integrated evidence to guide the design and prioritization of future research. The results have important real-world implications, supporting cautious implementation while underscoring the need for more robust trials, particularly in resource-limited settings. Trial Registration: PROSPERO CRD42023492123; https://www.crd.york.ac.uk/PROSPERO/view/CRD42023492123

20 April 2024 in JMIR Preprints
Verified
Preprint
Open access
YWYanyun Wu
Yanyun Wu
YCYangfan Cheng
Yangfan Cheng
YXYi Xiao
Yi Xiao
HSHuifang Shang
Huifang Shang
RORuwei Ou
Ruwei Ou
BACKGROUND Parkinson disease (PD) is a common neurodegenerative disease characterized by both motor and nonmotor symptoms. Cognitive impairment often occurs early in the disease and can persist throughout its progression, severely impacting patients’ quality of life. The utilization of machine learning (ML) has recently shown promise in identifying cognitive impairment in patients with PD. OBJECTIVE This study aims to summarize different ML models applied to cognitive impairment in patients with PD and to identify determinants for improving diagnosis and predictive power for early detection of cognitive impairment. METHODS PubMed, Cochrane, Embase, and Web of Science were searched for relevant articles on March 2, 2024. The risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Bivariate meta-analysis was used to estimate pooled sensitivity and specificity results, presented as odds ratio (OR) and 95% CI. A summary receiver operator characteristic (SROC) curve was used. RESULTS A total of 38 articles met the criteria, involving 8564 patients with PD and 1134 healthy controls. Overall, 120 models reported sensitivity and specificity, with mean values of 71.07% (SD 13.72%) and 77.01% (SD 14.31%), respectively. Predictors commonly used in ML models included clinical features, neuroimaging features, and other variables. No significant heterogeneity was observed in the bivariate meta-analysis, which included 12 studies. Using sensitivity as the metric, the combined sensitivity and specificity were 0.76 (95% CI 0.67-0.83) and 0.83 (95% CI 0.76-0.88), respectively. When specificity was used, the combined values were 0.77 (95% CI 0.65-0.86) and 0.76 (95% CI 0.63-0.85), respectively. The area under the curves of the SROC were 0.87 (95% CI 0.83-0.89) and 0.83 (95% CI 0.80-0.86) respectively. CONCLUSIONS Our findings provide a comprehensive summary of various ML models and demonstrate the effectiveness of ML as a tool for diagnosing and predicting cognitive impairment in patients with PD. CLINICALTRIAL PROSPERO CRD42023480196; https://www.crd.york.ac.uk/PROSPERO/view/CRD42023480196

25 September 2023
Verified
Conference Paper
Closed access
PDF file
ZMZiqiang Ming
Ziqiang Ming
XLXiang Li
Xiang Li
XDXinwei Du
Xinwei Du
Chuan YuanChuan Yuan
Chuan Yuan
BLBo Li
Bo Li
JLJianquan Liao
Jianquan Liao
Three-phase LCL-type grid-connected inverter is an important interface element of centralized photovoltaic (PV) gridconnected system. However, the inherent resonance in the LCL filter may lead to system instability. This research suggests an improved capacitor current feedback active damping (CCFAD) approach to address this issue. Firstly, the sequence impedance model of the PV grid-connected inverter is established using harmonic linearization method, and the resonant characteristics of the PV grid-connected system is revealed based on stability criterion. Subsequently, based on the proportional CCFAD strategy, an improved CCFAD strategy with delay compensation is proposed, which not only widens the positive damping zone of the traditional CCFAD, but also effectively improves the phase margin of the output impedance of the PV grid-connected inverter. Finally, the effectiveness of the proposed active damping control strategy is verified by simulation results.